Related Experiment Videos
RAD, a new immunosuppressive macrolide in murine corneal transplantation.
A Reis1, M Megahed, T Reinhard
1Eye Clinic, Heinrich-Heine University, Düsseldorf, Germany. reis@uni-duesseldorf.de
Summary
RAD, a novel immunosuppressant, significantly prolongs corneal allograft survival in rats by reducing immune cell infiltration. This macrolide shows promise for high-risk keratoplasty, warranting further study.
Area of Science:
- Immunology
- Ophthalmology
- Pharmacology
Background:
- RAD is a novel macrolide immunosuppressant impacting growth factor signaling.
- Investigated RAD's efficacy in preventing allograft rejection in a rat corneal transplant model.
Purpose of the Study:
- To evaluate the immunosuppressive potency of RAD in inhibiting allograft rejection.
- To assess RAD's effect on corneal transplant survival and immune cell infiltration.
Main Methods:
- Orthotopic allogeneic penetrating keratoplasty performed in Lewis rats using Fisher rat corneas.
- Animals treated with RAD (1.5 or 2.5 mg/kg/day) or cyclosporin A (CSA, 10 mg/kg/day) for 18 days.
- Transplant survival monitored; immunohistology assessed CD4+, CD8+, CD45+ cell infiltration.
Main Results:
- RAD significantly prolonged corneal allograft survival compared to controls.
- RAD demonstrated efficacy comparable to CSA in extending transplant survival.
- RAD treatment reduced CD4+, CD8+, and CD45+ immune cell infiltration in grafts.
Conclusions:
- Oral immunosuppression with RAD effectively prolongs corneal allograft survival.
- RAD shows potential as an immunosuppressive therapy for high-risk keratoplasty.
- Further preclinical and clinical investigations of RAD are recommended.